Autopsy report · NCT00100828

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

“Closed due to early stopping rule”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 4 years before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 10 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor type

University, hospital or other

Conditions

Head and Neck Cancer

Interventions

irinotecan hydrochloride

Participants

6

Sites

2

Countries

United States

Trials that died the same way

• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
  “Closed early due to slow accrual” (71% match in meaning)
• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (69% match in meaning)
• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
  “Closed early due to poor accrual.” (67% match in meaning)
• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
  “Closed prematurely because the accrual was not achieved” (62% match in meaning)
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer
  “Closed early for poor accrual.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.